Modality
Nanobody
MOA
GLP-1/GIP
Target
CD20
Pathway
Ferroptosis
MG
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
~Feb 2017
→ ~May 2018
NDA/BLA
Aug 2018
→ Nov 2027
NDA/BLACurrent
NCT03991234
1,304 pts·MG
2025-07→2027-11·Terminated
NCT06577846
2,074 pts·MG
2018-08→TBD·Completed
3,378 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-271.7y awayPh3 Readout· MG
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Complet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2027-11-27 · 1.7y away
MG
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03991234 | NDA/BLA | MG | Terminated | 1304 | SRI-4 |
| NCT06577846 | NDA/BLA | MG | Completed | 2074 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| BEA-4274 | Beam | Phase 1/2 | ALK |